Merck registers tulisokibart trials in sarcoidosis, uveitis; backs prostate cancer ADC study

Merck Sharp & Dohme posted two new Phase 2 studies of tulisokibart (MK-7240) and is listed as a collaborator on a separate Phase 2 trial of ifinatamab deruxtecan.

• Tulisokibart, also known as MK-7240 or PRA023, entered a Phase 2 randomized, placebo-controlled trial in active pulmonary sarcoidosis, sponsored by Merck Sharp & Dohme. The study is recruiting, with an estimated enrollment of 158 participants¹, and its primary outcome is worsening of PS based on clinical judgment, pulmonary function tests, and/or impaired quality of life as measured by the King's Sarcoidosis Questionnaire (KSQ)-lung score¹.
• Tulisokibart also began a Phase 2b, randomized, placebo-controlled study in active noninfectious intermediate, posterior, or panuveitis, sponsored by Merck Sharp & Dohme. The trial is recruiting, with estimated enrollment of 87 participants², and includes a 50-week double-blind period and a 134-week long-term extension².
• Ifinatamab deruxtecan (I-DXd), an antibody-drug conjugate, is being studied in a Phase 2 single-arm trial for neuroendocrine prostate cancer, sponsored by Rahul Aggarwal with Daiichi Sankyo and Merck Sharp & Dohme LLC listed as collaborators. The study is not yet recruiting, with estimated enrollment of 30 participants³, and its primary objective is to determine the objective response rate of I-DXd in de novo or treatment-emergent metastatic neuroendocrine prostate cancer³.